Abstract
Background After decades of rising life expectancy, life expectancy in the developed West is currently stagnated and remains shorter in men than women. Very well-established evolutionary biology theory suggests that lifespan trades off against reproductive success, possibly sex-specifically. We examined whether a key driver of reproductive success, testosterone, affected lifespan using a Mendelian randomization study of longevity in the UK Biobank to obtain unbiased estimates, along with control exposures.
Methods We applied published genetic instruments for testosterone to obtain inverse variance weighted estimates of associations with longevity, proxied by survival to (i.e., age at) recruitment, in 167020 men and 194174 women. We similarly obtained estimates for smoking initiation, and absorbate, a marker of vitamin C metabolism, because. We also conducted sensitivity analysis.
Results Overall testosterone was associated with poorer survival (0.10 years younger at recruitment per effect size of testosterone, 95% confidence interval (CI) 0.004 to 0.20). As expected, smoking initiation was also associated with poorer survival (0.37 years younger, 95% CI 0.25 to 0.50), but not absorbate (0.01 years younger, 95% CI −0.09 to 0.11). Sensitivity analysis generally gave a similar interpretation
Conclusions Consistent, with well-established theory, testosterone reduced longevity. Several aspects of a healthy lifestyle (such as a low animal fat diet) and several widely used medications (such as statins, metformin, dexamethasone and possibly aspirin) happen to modulate testosterone. Explicitly designing interventions sex-specifically based on these insights might be a means of addressing stagnating life expectancy and sexual disparities in life expectancy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank has ethics approval from the North West Multi-centre Research Ethics Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This study uses data from the UK Biobank that is publicly available or available on application.
